| ALDH2与乳腺浸润性微乳头状癌新辅助化疗的相关性研究 |
| |
| 引用本文： | 付怡如,时倩倩,牛琛,李帅,付丽.ALDH2与乳腺浸润性微乳头状癌新辅助化疗的相关性研究[J].中国肿瘤临床,2021,48(23):1201-1207. |
| |
| 作者姓名： | 付怡如 时倩倩 牛琛 李帅 付丽 |
| |
| 作者单位： | 天津医科大学肿瘤医院乳腺病理科，国家肿瘤临床医学研究中心，天津市肿瘤防治重点实验室，天津市恶性肿瘤临床医学研究中心，乳腺癌防治教育部重点实验室 （天津市300000） |
| |
| 基金项目： | 本文课题受国家自然科学基金项目（编号:81672637，81872164）资助 |
| |
| 摘 要： | 目的 检测乳腺浸润性微乳头状癌（invasive micropapillary carcinoma，IMPC）中乙醛脱氢酶2（acetaldehyde dehydrogenase 2，ALDH2）的表达，探讨ALDH2表达水平对IMPC患者新辅助化疗方案的指导意义。 方法 选取2009年1月至2014年5月298例于天津医科大学肿瘤医院行新辅助化疗（neoadjuvant chemotherapy，NAC）的乳腺癌患者的临床病理资料，其中IMPC为84例、浸润性导管癌非特殊型（invasive ductal carcinoma no special type，IDC-NOS）为214例。采用倾向评分匹配法成功匹配84例IMPC与IDC-NOS，检测ALDH2在IMPC组和IDC-NOS组中的表达差异，分析IMPC患者中ALDH2不同表达组的临床病理特征、NAC反应分级与预后相关性。 结果 ALDH2在IMPC中的表达水平为48.8%（41/84），显著高于IDC-NOS的33.3%（28/84），两者比较差异具有统计学意义（P=0.041）；IMPC患者中ALDH2表达水平与N分期（rs=0.348，P=0.017）及p53突变水平（rs=0.262，P=0.016）呈正相关，与NAC反应分级及无病生存率（disease-free survival，DFS）呈负相关（均P<0.05）。 结论 在IMPC中ALDH2高表达且与NAC反应分级及DFS呈负相关。针对ALDH2高表达的IMPC患者应尽早行手术切除，以延长生存预后。
|
| 关 键 词： | 乙醛脱氢酶2 浸润性微乳头状癌 乳腺癌 新辅助化疗 |
| 收稿时间： | 2021-07-22 |
Study on the relationship between acetaldehyde dehydrogenase 2 and neoadjuvant chemotherapy for invasive micropapillary carcinoma of breast |
| |
| Affiliation: | Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education), Tianjin 300000, China |
| |
| Abstract: | Objective To detect the expression of acetaldehyde dehydrogenase 2 (ALDH2) in invasive micropapillary carcinoma (IMPC) and explore the significance of ALDH2 expression levels in guiding neoadjuvant chemotherapy regimen for patients with IMPC of breast. Methods Clinicopathological data of 298 patients with breast cancer who underwent neoadjuvant chemotherapy (NAC) at Tianjin Medical University Tumor Hospital from January 2009 to May 2014 were assessed. Of the 298 patients, 84 with IMPC and 214 with invasive ductal carcinoma of no special type (IDC-NOS). Eighty-four patients with IMPC and IDC-NOS were successfully matched by the propensity score matching method. Difference in the expression of ALDH2 between the IMPC and IDC-NOS groups was detected, and clinicopathological features, NAC response grade, and prognosis of patients with IMPC in different ALDH2 expression groups were analyzed. Results The expression level of ALDH2 in IMPC was 48.8% (41/84), which was significantly higher than that in IDC-NOS (33.3%, 28/84), and the difference was statistically significant (P=0.041). In the IMPC group, the expression level of ALDH2 was positively correlated with N stage (rs=0.348, P=0.017) and p53 mutation level (rs=0.262, P=0.016) and negatively correlated with the grade of NAC response and disease-free survival (DFS) (all P<0.05). Conclusions ALDH2 was highly expressed in IMPC and was negatively correlated with NAC response grade and DFS. IMPC patients with high ALDH2 expression should be surgically treated as soon as possible to prolong survival. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载全文 |
|
